🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

The Zacks Analyst Blog Highlights: Medtronic, Chubb, Exelon, Check Point Software And Macy's

Published 11/13/2016, 09:30 PM
Updated 07/09/2023, 06:31 AM
US500
-
MDT
-
EXC
-
CB
-
M
-

For Immediate Release

Chicago, IL – November 14, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Medtronic (NYSE:MDT) (NYSE:MDTFree Report), Chubb (NYSE:CB) (NYSE:CBFree Report), Exelon (NYSE:EXC) (NYSE:EXCFree Report),Check Point Software (NASDAQ:CHKPFree Report) and Macy's (NYSE:M) (NYSE:MFree Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Today

Today's Research Daily features new research reports on 16 major stocks, including Medtronic (NYSE:MDTFree Report), Chubb (NYSE:CBFree Report) and Exelon (NYSE:EXCFree Report). These reports have been hand-picked from among the roughly research reports issued by our analyst team today. You can see the complete list of today's research reports here >>>

Medtronic shares have gained more than 7% year-to-date, outperforming the peer medical devices space, on the back of the company's recent product launches and FDA approvals. The analyst likes the $1.1 billion acquisition of Heartware International, which is expected to significantly boost its Cardiac Rhythm & Heart Failure business, but worries about the company's sluggish spine business over the past few quarters. (You can read the full research report on Medtronic here>>)

Chubb shares have lagged the insurance space this year, but the Zacks analyst thinks the company stands a good chance of taking leadership in the P&C space, benefiting from complementary products and services. Its inorganic growth story seems impressive and should help it achieve higher long-term ROE. A strong capital position helps Chubb to engage in shareholder friendly moves and invest in strategic initiatives that drive growth. However, the company’s exposure to cat loss (estimates $200 million cat loss in fourth quarter from Hurricane Matthew) and a low interest rate environment are headwinds. The recent uptrend in long-term interest rates is beneficial to Chubb and others in its space. (You can read the full research report on Chubb here>>)

Exelon shares have been strong performers this year, but they have come under pressure in recent sessions as long-term interest rates have trended up following the election. The analyst emphasizes that the company has benefitted from new electric rates and above-average temperatures in its service territories. Moreover, Exelon is gaining from the Pepco Holdings acquisition, which contributed $130 million to its earnings in the reported quarter. However, Exelon is subject to the impact of commodity price volatility, and price fluctuation in the wholesale markets. (You can read the full research report on Exelon here>>)

Other noteworthy reports we are featuring today include Check Point Software (NASDAQ:CHKPFree Report) and Macy's (NYSE:MFree Report).

Today's Private Buys & Sells from Zacks Research
While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on MDT - FREE

Get the full Report on CB - FREE

Get the full Report on EXC - FREE

Get the full Report on CHKP - FREE

Get the full Report on M - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.



MEDTRONIC (MDT): Free Stock Analysis Report

CHUBB LTD (CB): Free Stock Analysis Report

EXELON CORP (EXC): Free Stock Analysis Report

CHECK PT SOFTW (CHKP): Free Stock Analysis Report

MACYS INC (M): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.